Syncona founds new gene therapy company
Syncona, the UK life sciences investor, has launched a new gene therapy company, through a £45m series A private fundraising round. The company could be a future candidate for a lucrative biotech listing.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts